Investors act early as pharmacodynamic data drive Morphic shares
Positive data could read through to rest of Morphic’s pipeline
With pharmacodynamic data driving a gain of over $1.6 billion in market cap, Morphic is the latest example of how deep insights into structural biology are pushing clinical inflection points earlier.
Shares of Morphic Holding Inc. (NASDAQ:MORF) rose 135% to $84.85 on Monday after the company said lead oral integrin inhibitor MORF-057 achieved receptor occupancy levels of greater than 95% in a Phase I study, in addition to being safe. The move brings the company’s market cap to more than $2.6 billion...